PCN17 ONCOLOGY DRUGS GAINING FDA APPROVAL FOR LOW SURVIVAL...

Value in Health 2019 / 05 Vol. 22

PCN17 ONCOLOGY DRUGS GAINING FDA APPROVAL FOR LOW SURVIVAL INDICATIONS AND ENTERING FIRST TO MARKET ARE ASSOCIATED WITH LESS MATURE CLINICAL DATA COMPARED TO LATER ENTRANTS

Shohet, S., Schmetz, A., Ansart, S., Feuilly, M., Shah, S., Hollywood, A., Laughlin, W.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.141
Date:
May, 2019
File:
PDF, 706 KB
english, 2019
Conversion to is in progress
Conversion to is failed